UPM Biomedicals
Develops wood-based nanofibrillar cellulose hydrogels and bioinks for 3D bioprinting and cell culture, enabling sustainable, animal-free biomedical applications like tissue engineering and drug development.
- CEO / Founder
- Johana Kuncová-Kallio
- Team Size
- 11-50
- Stage
- Active
Technology & Products
Key Products
GrowDex hydrogels; GrowInk bioinks; FibDex wound dressings; FibGel injectable hydrogel
Technological Advantage
Proprietary nanocellulose process protected by over 300 patents, enabling tunable stiffness and reproducibility in hydrogels, with ISO 13485 manufacturing for clinical use.
Differentiation
Value Proposition
Provides biocompatible, non-animal-derived hydrogels that mimic the extracellular matrix, reducing reliance on animal components and supporting consistent cell growth for research and clinical applications like wound care and bioprinting.
How They Differentiate
Offers wood-based, non-animal-derived nanocellulose hydrogels with over 300 patents, providing sustainable alternatives to competitors using animal-derived materials like collagen, with proven biocompatibility in clinical applications like FibDex wound care.
Market & Competition
Target Customers
Pharmaceutical companies, academic researchers, medical device manufacturers, distributors
Industry Verticals
Life Sciences; Medical Devices; Pharmaceuticals; Research
Competitors
BICO; CollPlant Biotechnologies; Organovo
Growth & Milestones
Growth Metrics
More than 300 patents protect products; 7,784+ LinkedIn followers; Products used in 3D bioprinting, tissue engineering, and advanced wound care applications
Major Milestones
Launched FibDex wound dressing in 2020 (class IIb medical device); Launched FibGel injectable hydrogel in 2024; Collaboration with CELLINK in 2021 for bioprinting developments; Distribution agreement with Brinter in 2023 for GrowInk bioinks
Notable Customers
Brinter; Cellbox; Aalto University